SL
Silence Therapeutics plc
SLN · NASDAQ
$12.46 -4.96% (-$0.65)
1M -13.17%
Market Cap $588.5M
P/E Ratio -
Div. Yield -
ROE 106.90%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 15.30x
P/S 958.07x
EV/FFO N/A
Growth
22 /100
Declining Book val. growth 41.33%
Rev. growth 68.36%
FCF growth N/A
Profitability
20 /100
Weak Net margin 9,755.61%
Op. margin 11,003.00%
FCF margin 6,893.22%
Quality
0 /100
Poor ROE 106.90%
ROA 56.32%
Asset turnover 0.01x
Debt
33 /100
High Current ratio 7.42x
Debt/Equity -0.00x
Net debt/EBITDA N/A
Stability
41 /100
Moderate Rev. volatility 90.95%
EPS volatility 11.98%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Upcoming events
05 NOV
Earnings
Upcoming earnings report